Get started

Potential

Long. 20% increase potential for 10 daysThe trend that this 180 day chart has presented is very consistent. This past week (10/9-11) I was watching the price action of BLNK as it seemed it has finally reached a new bottom around 2.38. Today I watched to see if it would break that low and it did not: After 14 red days, BLNK has finally rebounded off its bottom to 2.49. If it follows its 6 month pattern, BLNK will trend upwards for the next week and a half. 2.38 is now BLNK's support and I will close my positions if it drops below 2.38 or if it fails to meet a new high tomorrow.
NASDAQ:BLNKLong
by Closedeals
Will Gold hit 1948 degrees Fahrenheit and MELT to the floor???This is a AquaZition Zonezzz Trade Idea on the 3 day chart... Please read chart for my analysis It's a method I created due to failing in many other methods, and needing to help eliminate my emotion in the game. It's definitely my secret sauce, and you are welcome to join me~ God inspired me to put this approach together, and it blows my mind how amazing it truly is... God is good!!! OANDA:XAUUSD My Telegram name is the same as here, hit me up, let's trade talk!!!
FOREXCOM:XAUUSDShort
by Golden_Boy_618
2
Very interesting bullish SHARK pattern on BATBCBAT completed bullish Shark pattern. The Potential Reversal Zone consist of XA projection at 1.13 and BC projection at 1.618. Currently Price Action testing at the second time the bottom and there is potential double bottom forming. Key resistance zone before touch of Point Of Controll at 4205 sats. is between 2948 and 3163 sats. It can be now perfect opportunity for trade execution. Buy some BAT, place stoploss below the green support and watch the Price Action carefully when it hit the key resistance zone - there can be first target, but it has much bigger potential when bulls break-out this resistance. Other target zones are on the chart. Good luck!
Long
by HarmonicParadise
2
MU - LONG - Double bottom to 52.50- Double bottom at support. Micron is ready to fly, but I will wait a lite pullback at 35.00-35.50 - Strong stock on strong indusrty (Semiconductor). MU as been upgraded by Needham, from hold to buy at 50.00 as target. - Very trong fundamental : > P/E 3.57 > EPS : 157.6% this year Waiting for a lite pullback to buy and fly to 52.50 as potential and at is all time high at 64.50. I will update it regularly. Follow MU for development. I wish you a great trading day! Waz-
NASDAQ:MULong
by Wazaby
CRTX Strong watch potential unicorn 2020Please bear with me (or bull with me in a year) as I am new to this. I am new to investing and have been following biotech IPOs recently. I am just starting to learn technical analysis so I will have to update this later when there is more data to analyze and when I learn how to do that. Also disclaimer: I have an MD background but do not have any stake in this company yet. All information contained in this post about the company is available on the company site. GAIN trial: 500 subjects, each studied for 4 months, enrolling right now. This likely will not be published until Late 2019 at the very earliest based off of my experience in medical research as an MD. My optimistic guess is by mid 2020 it will be submitted, published mid to late 2020. If there are serious drug complications this would likely push back their timeline, but if things go extremely well its not unheard of to stop the blinding and begin treating everyone with the study drug (this would be a sign to me to buy like its going out of style.) After they prepare and submit a NDA, the FDA has 60 days to review it. I think the earliest this drug hits the market if it goes through is 2021. The premise of the drug is based off of a newly demonstrated theory on the nature of Alzheimer's disease. According to the Texas Department of Health and Human services, 5.8 million Americans have Alzheimers. This represents the current American market. With an aging boomer population the incidence and prevalence will likely increase. Sciences Advances Jan 2019 "porphyromonas gingivalis in Alzheimer's brains: Evidence..." convinced me that amyloidosis is a result of bacterial colonization of the brain in older people, and Dr. Moir and Dr. Tanzi of Mass General posted similarly on AlzForum. Cor388 is the only gingipain inhibitor being developed that I could find online. So they have the only drug in development, its in phase 2/3 right now. Reuters on success rates for study drugs - basically the problem is that Phase 2 results predict phase 3 and FDA approval, and we only have phase 1 info. Its still risky, but I think the upside of having a monopoly on a new class of drug is high enough to warrant the risk. If they show this drug can improve rather than just slow the progression of Alzheimer's, they will have a drug that does something that no other Alzheimer's treatment has ever done before. -That is why this is a potential unicorn.- The effect on public AND market psychology would be astounding. That being said, after the new IPO hype wears off and we get some quarterly loss reports, price will likely drop BEFORE drug trial results come out, and if they're good (as I expect them to be) we should see either a bubble form or a rocket ship take off. Pre-phase 2/3 results represents my best window for entry for a long term investment.
CLong
by Happygains